| Inventor |
|---|
| Pranab K Das |
| SKU: | 154108 |
|---|---|
| Product description: | Vitiligo is a long-term skin condition characterised by patches of the skin losing their pigment. The patches of skin affected become white and usually have sharp margins. The exact cause of vitiligo is unknown however it is believed to be due to genetic susceptibility that is triggered by an environmental factor such that an autoimmune disease occurs. High frequencies of melanocyte-reactive cytotoxic T cells in the peripheral blood of vitiligo patients and the observed correlation between peri-lesional T-cell infiltration and melanocyte loss in situ suggest the important role of cellular autoimmunity in the pathogenesis of this disease. Primary T-cells isolated from both the peri-lesional and non-lesional skin biopsis can be used as a research tool. |
| Conditional: | No |
| Production details: | T cell lines were generated from fresh skin biopsies. Biopsies were incubated in a 24 well plate coated with 10ÄÂ??g/well fibronectin to facilitate spontaneous migration of T cells from the biopsy into the Iscove’s Modified Dulbecco Medium (IMDM) supplemented with 10% normal human serum, 1mM glutamine, 100U/ml penicillin and 100ÄÂ??g/ml streptomycin. After 5 days extravasated skin T cells were transferred to an uncoated 24 well plate and expanded by mitogenic stimulation with 0.05% PH… |
| Parental cell line: | Non-lesional skin of vitiligo patient |
| Disease: | Vitiligo |
| Cat. #: | 154108 |
|---|---|
| Unit size: | 1×10^6 cells / vial |
| Research Fields: | Cell biology; Immunology |
| Organism: | Human |
| Model: | Primary line |
| Format: | Frozen |
|---|---|
| Shipping conditions: | Dry ice |
| Growth medium: | Iscove’s Modified Dulbecco Medium (IMDM) supplemented with 10% normal human serum, 1mM glutamine, 100U/ml penicillin and 100 ??g/ml streptomycin plus mitogenic stimulation with 0.05% PHA in the presence of irradiated allogeniec feeder cells consisting of PBMCs from two unrelated donors EBV transformed B cells and 10U/ml recombinant human IL-2 for 10 days. |
| References: |
Wankowicz-Kalinska et al. 2003. Lab Invest. 83(5):683-95. PMID: 12746478. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.